Silylated withaferin A analogues display multi-stage HIV-1 inhibition with optimized in vitro potency and favorable predicted ADME properties

Despite advances in antiretroviral therapy, toxicity problems, emergence of drug-resistant HIV-1 (human immunodeficiency virus 1) strains and viral reservoirs, emphasize the urgent need for new anti-HIV drugs. Withaferin A, a natural steroidal lactone first isolated from the medicinal plant Withania somnifera (L.) Dunal (Ashwagandha), has emerged as a promising lead scaffold with proven pharmacological properties. Based on previous studies highlighting the therapeutic potential of withaferin A and the emerging role of organosilicon motifs in drug design, we explored and enlarged the chemical space of this steroidal framework as a basis to broaden the current antiretroviral chemotherapy. The present study reports the synthesis of thirty withaferin A-silyl ether analogues, including two twin compounds and three silyl-ester analogues reported for the first time. The antiretroviral activity of this compound series was evaluated, and five inhibitors were selected for mechanistic studies to define their mechanism of action in the HIV-1 replication cycle. Withaferin A and the selected analogues primarily acts through viral integration and post-transcriptional stages. Notably, some analogues redirect the withaferin A main mechanism, also affecting HIV envelope and reverse transcription. This multi-step behaviour may provide an advantage to overcome the drawbacks of the current therapy. In addition, structure-activity relationships and in silico ADME studies were employed to understand the structural requirements and pharmacokinetic properties of this series of analogues. The results herein underscore withaferin A as a versatile structural platform to develop new antiretroviral drugs.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-11-17
DOI
https://doi.org/10.1016/j.biopha.2026.120058
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Silylated withaferin A analogues display multi-stage HIV-1 inhibition with optimized in vitro potency and favorable predicted ADME properties

Manuela Beltrán, Luis Miguel Bedoya, Ignacio A. Jiménez, Ángel Amesty et al.
Biomedicine & Pharmacotherapy
HIV/AIDS drug development and treatment
article

Silylated withaferin A analogues display multi-stage HIV-1 inhibition with optimized in vitro potency and favorable predicted ADME properties

Manuela Beltrán, Luis Miguel Bedoya, Ignacio A. Jiménez, Ángel Amesty, Francisco Díez‐Fuertes, Javier García‐Pérez, José Alcamı́, Isabel L. Bazzocchi, Eduardo Hernández-Álvarez, María González-Linares, Ludovica Clani
article en

Abstract

Despite advances in antiretroviral therapy, toxicity problems, emergence of drug-resistant HIV-1 (human immunodeficiency virus 1) strains and viral reservoirs, emphasize the urgent need for new anti-HIV drugs. Withaferin A, a natural steroidal lactone first isolated from the medicinal plant Withania somnifera (L.) Dunal (Ashwagandha), has emerged as a promising lead scaffold with proven pharmacological properties. Based on previous studies highlighting the therapeutic potential of withaferin A and the emerging role of organosilicon motifs in drug design, we explored and enlarged the chemical space of this steroidal framework as a basis to broaden the current antiretroviral chemotherapy. The present study reports the synthesis of thirty withaferin A-silyl ether analogues, including two twin compounds and three silyl-ester analogues reported for the first time. The antiretroviral activity of this compound series was evaluated, and five inhibitors were selected for mechanistic studies to define their mechanism of action in the HIV-1 replication cycle. Withaferin A and the selected analogues primarily acts through viral integration and post-transcriptional stages. Notably, some analogues redirect the withaferin A main mechanism, also affecting HIV envelope and reverse transcription. This multi-step behaviour may provide an advantage to overcome the drawbacks of the current therapy. In addition, structure-activity relationships and in silico ADME studies were employed to understand the structural requirements and pharmacokinetic properties of this series of analogues. The results herein underscore withaferin A as a versatile structural platform to develop new antiretroviral drugs.

Biomedicine & PharmacotherapyVol. 205
Universidad de La Laguna (ES), Instituto de Salud Carlos III (ES), Centro Nacional de Microbiologia (ES)
Ministerio de Ciencia, Innovación y Universidades, Universidad Complutense de Madrid, Agencia Estatal de Investigación
Good health and well-being
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon